Aemetis Q4: The Catalysts Finally Print, and the Thesis Inflects
Key Takeaways
- This is the inflection quarter. Q4 swung to a positive gross profit of $7.7M (from a $2M loss a year ago), the operating loss collapsed to $(2.5)M (from $(13.5)M), and the net loss narrowed to $(5.3)M, or $(0.08) per share, from $(0.32). The stock jumped 24.7% to $1.92 on 4.4x average volume.
- The proof point we said we needed before upgrading arrived: Aemetis recognized roughly $10.3M of production tax credits in Q4 (including its first ~$5M of 45Z, monetized in the final days of the quarter), and the dairy biogas segment turned profitable for the full year with $12.2M of segment net income and Q4 production up 61% year over year.
- The biggest single overhang lifted. Treasury issued final 45Z guidance on February 4, 2026 (176 pages, "no surprises," consistent with the One Big Beautiful Bill), removing the negative-51 carbon-intensity distortion that had suppressed roughly 90% of the company's 45Z value. Only the mechanical DOE GREET spreadsheet remains, expected "this month," after which management can calculate and recognize the full credit.
- 2026 self-help is now funded, not hoped for: the ~$40M MVR project is past half-complete, fully financed with no equity dilution, and adds an estimated ~$4M/month of 45Z-plus-MVR cash flow starting in H2; LCFS credits have risen from $40 to $70 with management seeing a path to $100+. Management expects 2026 cash flow "significantly in excess of 2025."
- Rating: Upgrading to Outperform from Hold. Two quarters of catalyst slippage have given way to actual gross profit, actual credit recognition, and a finalized federal rule, while the stock still sits near multi-year lows with the India subsidiary IPO ahead as a separate value-surfacing event. The risk/reward has decisively skewed up; the residual risks (the DOE spreadsheet, the refinancing, IPO execution) are now timing on a thesis that is printing, not an unproven option.
Results vs. Consensus
| Metric | Q4 2025 | Q4 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Revenue + tax credits | $53.7M | $47.0M | $208.0M | $268.0M |
| Revenue (GAAP) | ~$43.3M | n/a | $197.6M | $267.6M |
| Gross Profit / (Loss) | $7.7M | $(2.0)M | n/a | n/a |
| Operating Loss | $(2.5)M | $(13.5)M | $(37.2)M | n/a |
| Net Loss | $(5.3)M | $(16.2)M | $(77.0)M | $(87.5)M |
| EPS (GAAP) | $(0.08) | $(0.32) | ~$(1.50) | n/a |
| Production tax credits recognized | $10.3M | ~0 | $10.4M | ~0 |
Against a thinly-covered Street looking for a substantially larger loss, the $(0.08) print was a clear upside surprise, and the 24.7% reaction confirms it. (One widely-syndicated feed showed a stale $(0.24)/$(0.28) estimate pair that does not reconcile with the authoritative $5.3M net loss; we disregard it. The unambiguous facts are the first positive gross profit, the first credit recognition, and the smallest quarterly loss of the year.)
Quality of the Print
- Revenue: Reported total income of $53.7M (revenue plus credits) understates the operational improvement because the quality shifted toward high-margin credit income. The $10.3M of production tax credits is the first quarter in which the credit machine actually contributed to the P&L rather than accruing off-statement, which is precisely the transition the prior two recaps were waiting on.
- Margins: The swing to a $7.7M gross profit is the single most important number in the release. It reflects the credit recognition plus the operational ramp (higher ethanol grind, the dairy fleet at 12 digesters with the LCFS uplift active). Full-year gross economics remain pressured, but the Q4 exit margin is the relevant signal for 2026.
- EPS: A $(0.08) loss versus $(0.32) a year ago, on a net loss of $5.3M (the smallest of the year), is a genuine bottom-line inflection. Interest expense remains the structural drag, which is exactly what the pending refinancing and the rising credit cash are meant to address; for the first time the credit cash is real.
Segment Performance
| Segment | FY 2025 Revenue | Volume / KPI | 2025 Milestone | 2026 Driver |
|---|---|---|---|---|
| California Ethanol (Keyes) | $158M | ~65M gal capacity, ~90% utilization | ILUC penalty removed; ~$12M/yr 45Z run-rate | MVR completion adds ~$32M/yr cash |
| India Biodiesel | $29.7M | ~80M gal capacity | Deliveries recovered post-pause | Global biofuels IPO (biodiesel + CBG + SAF) |
| Dairy RNG (Biogas) | $12.2M segment net income | ~405,000 MMBtu, 12 digesters, +61% Q4 YoY | Segment profitability + first 45Z | Digesters doubling (15 H2S units contracted) |
Dairy Renewable Natural Gas (Biogas)
The segment the whole thesis is built on delivered its breakout year: ~405,000 MMBtu of production across 12 digesters, Q4 production up 61% year over year, and, critically, positive segment net income of $12.2M for 2025 plus the first ~$5M of 45Z monetized in the final days of Q4. Looking ahead, equipment is contracted (H2S cleanup and biogas compression for 15 digesters) to roughly double the operating network, financed via the same 20-year structure used for Aemetis Biogas 1 and 2.
"Our dairy renewable natural gas platform reached an important [milestone] during 2025, achieving positive segment net income and EBITDA while production increased 61% year over year in the fourth quarter. We generated net income of $12.2 million in our biogas segment in 2025." — Eric McAfee, Chairman & CEO
Assessment: Segment profitability plus the first 45Z dollars is the proof of concept the equity needed. With the digester count contracted to double and 45Z value about to be unlocked at full rate, this is now a visibly compounding business rather than a perpetual build-out. The Bloomberg-cited ~$7/gallon × 8.6 gallons/MMBtu (~$60/MMBtu) 45Z math, if anywhere near right, makes the segment's 2026 economics materially larger than 2025's.
California Ethanol
Keyes generated $158M of revenue at roughly 90% utilization of its ~65M-gallon capacity. Management framed ethanol as "two worlds": pre-MVR (currently ~$12M/year 45Z run-rate after the ILUC-penalty removal) and post-MVR, where eliminating 80% of natural-gas use both cuts cost and lifts 45Z/LCFS value, adding roughly $4M/month of combined 45Z-plus-MVR cash flow from H2 2026. The ~$40M MVR project is past half-built, fully financed, and dilution-free.
"Post-MVR, we get rid of 80% of our natural gas cost, but also 80% of the penalty... we should be running about $4 million a month on just the 45Z plus MVR starting in what we are currently targeting as the third quarter for the MVR." — Eric McAfee, Chairman & CEO
Assessment: The MVR is the clearest, most controllable self-help in the model: financed, half-done, and additive to cash flow in roughly half of 2026. Layered on top of an LCFS price that has gone from $40 to $70 with a path to $100+, the ethanol segment moves from low-margin ballast to a genuine cash contributor by year-end.
India Biofuels
India generated $29.7M of revenue with ~80M gallons of biodiesel capacity. The strategic story has expanded: management now frames the planned subsidiary listing as "the first global diversified biofuels IPO in the history of the India stock market," spanning biodiesel, compressed biogas (CBG), and sustainable aviation fuel, with the 80M-gallon plant positionable for SAF supplied to international airlines, partly insulating it from domestic biodiesel-demand timing. The end of discounted Russian and Iranian crude into India is framed as a structural tailwind for domestic biofuels.
"The business we are taking public in India is a global diversified biofuels IPO. We believe it will be the first global diversified biofuels IPO in the history of the India stock market." — Eric McAfee, Chairman & CEO
Assessment: The IPO scope has broadened from a biodiesel listing to a diversified biofuels platform, which both supports the $100–300M valuation framing from last quarter and reduces dependence on the lumpy OMC tender cycle. It remains a 2026 execution item, but it is now the clearest path to surfacing value the parent stock does not reflect, and it sits on top of an inflecting U.S. business rather than substituting for it.
Key Topics & Management Commentary
Overall Management Tone: The most confident posture in the four quarters we have covered, and for the first time the confidence was backed by printed results rather than forecasts. Management led with three concrete 2025 achievements (biogas profitability, the MVR build, and credit monetization) before turning to the policy catalysts, an inversion of the prior calls' policy-forward framing. The one consistent hedge remained the DOE GREET spreadsheet, repeatedly flagged as the last "should" in an otherwise de-risked sequence.
The 45Z Guidance Finalized: From "If" to "When"
The structural overhang that defined the prior two quarters substantially resolved. Treasury issued final 45Z guidance on February 4, 2026, consistent with the OBBB, removing the indirect-land-use penalty and the negative-51 distortion. Only the DOE GREET spreadsheet and the Calculated Emissions Value Letter (CEVL) process remain, both described as mechanical.
"The first step of that adoption is the Treasury's announcement on February 4, 2026 of 176 pages of tax guidance. There were no surprises in there, and we are now just awaiting the spreadsheet known as the GREET model from the Department of Energy." — Eric McAfee, Chairman & CEO
Assessment: This is the de-risking event. The "no surprises" finalized guidance converts the largest tail risk in the thesis (that the rule lands unfavorably) into execution timing (when the spreadsheet posts). With the first $5M of 45Z already monetized, the company has demonstrated it can transact; the remaining gate is administrative, not existential.
2026 Cash Flow "Significantly in Excess" of 2025
Management declined formal guidance but stated 2026 cash flow should be significantly above 2025, which captured "virtually no 45Z for the ethanol plant and minimal from RNG." The drivers: full 45Z recognition once the spreadsheet posts, LCFS at $70 and rising, the MVR contribution from H2, and the doubling digester network.
"We should be significantly in excess of 2025, which represented virtually no 45Z for the ethanol plant from a cash flow perspective, and minimal from our RNG... the 45Z production tax credit, which we have only monetized $5 million of... should be a significant generator." — Eric McAfee, Chairman & CEO
Assessment: The framing is credible precisely because 2025 already inflected on a tiny fraction of the eventual 45Z. If the segment generated $12.2M of biogas net income with essentially no 45Z, the step-up as the full credit recognizes is potentially large. This is the quantified version of the bull case finally meeting the income statement.
The MVR Project: Funded, Half-Built, Dilution-Free
The ~$40M MVR system is past the halfway point, fully financed, with the remaining spend over roughly four months and no ATM or equity funding attached. Contribution is expected to begin in Q3 2026 and be fully in place by Q4.
"Much of it is already made. We are well past half of that right now... it is fully financed and has no equity dilution through the completion of it." — Eric McAfee, Chairman & CEO
Assessment: A funded, dilution-free, ~$32M/year cash-flow project landing in H2 2026 is exactly the kind of self-help a levered small-cap needs, and the explicit "no dilution" statement directly addresses the equity-issuance risk we flagged last quarter. It moves a chunk of the 2026 improvement out of policy-dependent territory and into company-controlled execution.
2026 Capital Plan and Financing
Management detailed 2026 capex: the MVR wrap-up (~$40M total), a $27M contract for 15 H2S units, and roughly $70M for the digester build-out overlapping into 2027. Crucially, the MVR and H2S units are fully financed, and additional digesters use the established 20-year financing template (Aemetis Biogas 3–8 in process).
"We are fully financed for the completion of the MVR system. We are fully financed for the $27 million of H2S units. And as we roll out additional digesters, we expect to continue doing the type of 20-year financing which we have completed." — Eric McAfee, Chairman & CEO
Assessment: The growth capex is large relative to the company's size, but the financing template (20-year, asset-backed, partly USDA-guaranteed) is proven and the near-term projects are funded. The open item remains the long-term refinancing of the expensive Third Eye tranche, now better supported by demonstrated 45Z cash flow.
LCFS Price Trajectory
LCFS credits have risen from $40 to $70 over roughly nine months since the 20-year extension, against a $268 cap, with management seeing $100 plausible this year and $150+ next year as the program runs structural deficits.
"It has already gone from $40 to $70. We would not be surprised at all to see it hit $100 this year and $150 or more next year, as we continue to see quarterly deficits." — Eric McAfee, Chairman & CEO
Assessment: LCFS is the highest-conviction price tailwind in the model because it is market-realized rather than forecast, and it compounds directly on the negative-384 pathways. Each $10 move in the credit flows to the bottom line with little offsetting cost.
India Start-Stop and the Structural Shift
Asked whether investors must simply accept India's start-stop dynamics, management argued the structural backdrop has changed: with discounted Russian and Iranian crude cut off, India's import dependence makes domestic biofuels a strategic priority, mirroring ethanol's 1%-to-20% blend ramp over four years.
"Half a percent to 5% is a 10x expansion in the biodiesel business... we believe that biodiesel will have the similar kind of rise." — Eric McAfee, Chairman & CEO
Assessment: The geopolitical framing is plausible but the biodiesel blend ramp remains a policy bet on a government timeline, the same uncertainty that produced the prior tender pauses. The more durable point is that the SAF pivot and the diversified IPO structure reduce reliance on domestic biodiesel mandates.
Guidance & Outlook
No formal numeric guidance, but the qualitative 2026 framing is the strongest of the coverage period: cash flow "significantly in excess of 2025," driven by full 45Z recognition (post-DOE spreadsheet), LCFS at $70+ and rising, the MVR contribution from H2, a doubling digester network, and the India IPO.
| 2026 Driver | Framing | Timing | Status |
|---|---|---|---|
| 45Z full recognition | ~$60/MMBtu dairy economics (Bloomberg-cited) | After DOE GREET spreadsheet | Treasury guidance final; spreadsheet "this month" |
| MVR cash flow | ~$32M/yr; ~$4M/mo with 45Z | H2 2026 | Funded, half-built, no dilution |
| LCFS price | $70 → $100+ path | Through 2026 | Realized, rising |
| Digester network | Double the count (15 H2S units) | 2026–2027 | Contracted |
| India IPO | Diversified biofuels, $100–300M | 2026 | Red Herring forthcoming |
| Long-term refinancing | Expensive Third Eye tranche | 2026 | Now backed by proven 45Z cash |
Implied 2026 ramp: The building blocks are now largely funded or realized rather than promised. The swing factor is the magnitude of full 45Z recognition once the DOE spreadsheet posts, which management frames as a step-change given 2025 captured almost none of it.
Street at: Forward consensus remains scattered; the stock at $1.92 still sits in the lower half of its 52-week range despite the inflection, implying the market has not yet priced full 45Z recognition or the India IPO.
Guidance style: Still catalyst-narrated and DOE-dependent on the last step, but for the first time anchored by printed results (gross profit, credit recognition, segment profitability) rather than entirely forward promises.
Analyst Q&A Highlights
2026 Cash Flow Versus 2025
The most consequential exchange asked, absent formal guidance, whether 2026 could at least match 2025's cash flow. Management's answer reframed the question, arguing 2026 should significantly exceed 2025 because 2025 contained almost no 45Z.
Q: "I know you have not provided any formal guidance for 2026... But at a minimum, can we expect you to perform in line with sort of the cash flows we saw materialize in 2025?"
— Amit Dayal, H.C. Wainwright
A: "We should be significantly in excess of 2025, which represented virtually no 45Z for the ethanol plant from a cash flow perspective, and minimal from our RNG... the 45Z production tax credit, which we have only monetized $5 million of... should be a significant generator." — Eric McAfee, Chairman & CEO
Assessment: The answer is the clearest articulation yet of why the inflection matters: 2025's profitability improvement was achieved on essentially no 45Z. If the segment can be profitable without the credit, its full recognition is upside on top of an already-improving base. This is the crux of the upgrade.
MVR Timing and Whether Benefits Need Qualification
An analyst pressed on whether the MVR is already largely spent and whether its output, like RNG, needs a lengthy qualification process before monetization. Management confirmed it is past half-funded with no dilution and that MVR benefits monetize immediately.
Q: "Does the product coming out of this post-MVR need to be qualified, etcetera? Like the RNG had to go through an auditing process. Or will you be able to monetize right away those benefits?"
— Amit Dayal, H.C. Wainwright
A: "It is the MVR; we are monetizing it right away. There is not a long year or two-year delay." — Eric McAfee, Chairman & CEO
Assessment: Immediate monetization with no qualification lag and no dilution makes the MVR a clean, near-term, company-controlled cash contributor for H2 2026 — the most de-risked single line in the 2026 bridge.
2026 Capital Investment Plan
The opening question sought the 2026 capex split across RNG and ethanol. Management laid out the full program and emphasized that the near-term projects are financed.
Q: "Could you give us your expectations for capital investment for 2026 between your RNG and your ethanol business?"
— Derrick Whitfield, Texas Capital
A: "We will be wrapping up our MVR system. Total investment there is going to be roughly in the $40 million range... 15 contracted H2S units... about a $27 million contract... the build-out of those 15... roughly another $70 million on top of that... our refinancing existing debt includes financing for the assets I just mentioned." — Eric McAfee, Chairman & CEO
Assessment: The capex is heavy, but the disclosure that the MVR and H2S units are fully financed and the digesters use the proven 20-year template materially lowers the financing-risk read versus prior quarters. Growth is funded, not aspirational.
Ethanol EBITDA: Pre-MVR and Post-MVR
Asked how to think about ethanol EBITDA in 2026, management gave its most quantified answer of the call, splitting the year into pre- and post-MVR economics.
Q: "Margins are quite positive, even before accounting for the MVR investment. How are you thinking about EBITDA generation for that asset in 2026?"
— Derrick Whitfield, Texas Capital
A: "We are currently roughly at that $12 million a year run-rate [45Z]... Post-MVR... we should be running about $4 million a month on just the 45Z plus MVR starting in... the third quarter... And then, on top of that is the LCFS credit price increase." — Eric McAfee, Chairman & CEO
Assessment: A move from a ~$12M/year run-rate to ~$4M/month (~$48M annualized) on 45Z-plus-MVR, before LCFS upside, is a large step-up for one plant. Even haircutting management's framing, the ethanol segment's 2026 cash trajectory is materially better than its 2025 contribution.
Keyes Utilization and Expansion Optionality
An analyst noted Keyes has run near 90% for two years and asked about expansion once the MVR is complete. Management positioned expansion as a 2027 story behind the near-term focus on margin and cash flow.
Q: "It looks like [Keyes] has been running at about 90% capacity for the last two years. How comfortable are you with the current run-rate? And is there any potential plans to expand it once you are through the MVR project?"
— Dave Storms, Stonegate Capital
A: "We have not announced an expansion campaign yet... I would expect this is going to be more of a 2027 story... the margin improvement and sustainable positive cash flow from our existing asset is what we are focusing on right now." — Eric McAfee, Chairman & CEO
Assessment: The discipline to prioritize margin and cash generation from the existing asset over a capital-intensive expansion is the right call for a levered balance sheet, and it keeps E15-driven expansion as a free 2027 option rather than a near-term funding obligation.
OBBB Implementation Logistics
Questioning turned to how the One Big Beautiful Bill tailwinds get implemented in the near term. Management detailed the sequence from the July 2025 law to the February 2026 Treasury guidance to the pending DOE spreadsheet and CEVL process.
Q: "You have got some tailwinds coming out of the One Big Beautiful Bill... how do you see the logistics in the near term for the continued implementation of those tailwinds?"
— Dave Storms, Stonegate Capital
A: "The GREET model gets published this month by the DOE, and... in a matter of weeks, we should get a Calculated Emissions Value Letter... But the word 'should,' unfortunately, is where the uncertainty comes in." — Eric McAfee, Chairman & CEO
Assessment: Management's own flag on the word "should" is the honest residual risk. The legal and guidance steps are done; only the DOE's administrative posting remains, and the company has shown (with the $5M Q4 45Z sale) it can transact once the calculation is available. The risk is now weeks-to-a-quarter of timing, not a binary on the rule itself.
What They're NOT Saying
- A hard 2026 cash-flow or EBITDA number: "Significantly in excess of 2025" is directional. Given how much hinges on the magnitude of full 45Z recognition, the absence of even a wide range leaves the upside unquantified.
- A closed long-term refinancing: Near-term projects are financed, but the expensive Third Eye tranche refinancing is still described as a 2026 goal, not a done deal. It is better-supported now, but not closed.
- A firm DOE spreadsheet date: "This month" has been the framing before. Management's own "should" hedge concedes the one remaining external dependency is not in its control.
- India IPO timing precision: "This year" and "Red Herring forthcoming" without a filing date; the valuation band remains management's target, not the market's.
- Total debt and the maturity schedule: The call emphasized funded growth capex and improving cash flow but did not foreground the consolidated debt balance or near-term maturities, which remain the structural risk beneath an improving operating story.
Market Reaction
- Pre-print setup: AMTX closed at $1.54 the day before the release, up 10.8% year-to-date but down 13.0% over the trailing twelve months, near the low end of a compressed $1.25–$3.49 52-week range. Expectations were clearly muted after two quarters of catalyst slippage.
- Reaction-day session: The stock opened roughly flat ($1.50, -2.6%), then ran to an intraday high of $2.01 (+30.5%) and closed at $1.92, up 24.7% ($0.38), on roughly 4.4x average volume. The S&P fell 1.5% on the session.
This was the cleanest positive reaction of the coverage period and the mirror image of Q3's slump: the stock gapped little but ran hard through the session on heavy volume as the market digested the swing to gross profit, the first credit recognition, and the finalized 45Z guidance. After two quarters of selling the slip, the market bought the proof. The move off a depressed base, with the stock still below where the realized catalysts arguably justify, is consistent with the start of a re-rating rather than its completion.
Street Perspective
Debate: Is the Q4 Inflection Durable or a Credit-Timing Artifact?
Bull view: Gross profit turned positive, the biogas segment is profitable on almost no 45Z, the credit recognition has begun, and the largest rule risk is resolved; 2026 compounds from here as full 45Z, MVR, and rising LCFS layer in.
Bear view: A chunk of the Q4 swing is lumpy credit recognition ($10.3M of PTCs) that can be timed; strip it out and the underlying business is still loss-making with heavy leverage, and the "significantly higher 2026" rests on a DOE spreadsheet that keeps being "this month."
Our take: Both are partly right, but the bear case understates the structural change: the credit income is recurring policy revenue, not a one-off, and the segment was profitable even before it. We weight the inflection as durable and side with the bulls, which is the basis for the upgrade.
Debate: India IPO as the Next Leg
Bull view: A diversified global biofuels IPO (biodiesel + CBG + SAF) at a $100–300M target, against an ~$110M parent market cap post-rally, surfaces value the parent does not reflect and helps fund the refinancing.
Bear view: Foreign IPO timing slips, the valuation is unproven, and SAF/CBG in India are early-stage; the "first global diversified biofuels IPO" framing is marketing until a book builds.
Our take: It is a genuine, independent value-surfacing catalyst layered on an inflecting core, which is exactly the combination that supports an Outperform. We do not underwrite a specific valuation, but the optionality is now stacked on top of a printing thesis rather than substituting for an unproven one.
Debate: Does the Balance Sheet Still Cap the Upside?
Bull view: Near-term growth capex is fully financed without dilution, 45Z cash is now real and supports the refinancing, and the 20-year asset-backed template is proven; the leverage becomes manageable as cash flow steps up.
Bear view: The consolidated debt is still large, the expensive tranche is unrefinanced, and a heavy 2026–2027 capex program ($70M+ of digesters) leaves little margin for error if 45Z timing slips again.
Our take: The balance sheet remains the principal risk and the reason this is an Outperform rather than a high-conviction one, but the risk profile has improved materially: funded near-term capex, no-dilution MVR, and demonstrated credit cash. We accept the leverage in exchange for the now-printing catalyst stack and the depressed entry point.
Model Implications
| Item | Working Assumption | Watch For | Reason |
|---|---|---|---|
| Gross margin | Positive, expanding through 2026 | Sustained post-Q4 | Swung to $7.7M gross profit in Q4 |
| 45Z recognition | Step-change once DOE spreadsheet posts | GREET model + CEVL | Only $5M monetized so far; full rate pending |
| MVR contribution | ~$32M/yr; H2 2026 onset | Q3 2026 completion | Funded, half-built, no dilution |
| LCFS price | $70 → $100+ path | Quarterly program deficits | Up from $40; flows to bottom line |
| Dairy production | Doubling digester network | In-service dates | 15 H2S units contracted; +61% Q4 YoY |
| India IPO | Value-surfacing event 2026 | Red Herring filing | Diversified biofuels listing, $100–300M |
| Refinancing | Expensive tranche, 2026 | Close | Now backed by demonstrated 45Z cash |
Valuation impact: With the inflection printing and the largest rule risk resolved, we move off the bimodal "decline to set a target" posture toward a constructive view: the realized catalysts (gross profit, credit recognition, finalized guidance) plus the funded 2026 self-help (MVR, digesters) plus the India IPO optionality justify a stock meaningfully above the $1.92 reaction-day close. We frame fair value as a re-rating in progress rather than a point estimate, with the DOE spreadsheet and the first full-rate 45Z quarter as the near-term proof points that would close the remaining gap.
Thesis Scorecard Post-Earnings
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1 — Catalyst stack converging (45Z + LCFS + dairy RNG ramp) | Confirmed | First $10.3M PTCs recognized; biogas segment profitable ($12.2M); LCFS $40→$70 |
| Bull #2 — Best policy backdrop in years | Confirmed | Treasury 45Z guidance finalized Feb 4 ("no surprises"); ILUC penalty removed; E15 in CA |
| Bull #3 — India optionality (subsidiary IPO) | On track | Broadened to diversified biofuels IPO (biodiesel + CBG + SAF); Red Herring forthcoming |
| Bear #1 — Liquidity / leverage | Contained (improving) | Gross profit positive; near-term capex fully financed, no dilution; refi still open |
| Bear #2 — Credit-monetization timing/lumpiness | Easing | Treasury guidance final; first 45Z monetized; only DOE spreadsheet remains |
Overall: Thesis materially strengthened. Both bull pillars on the U.S. business confirmed by printed results, the biggest bear point (45Z timing) eased from materializing to a residual administrative step, and the balance-sheet risk improved with funded, dilution-free near-term capex. The India IPO optionality now sits on top of an inflecting core.
Action: Upgrade to Outperform from Hold. The proof point we required before paying for the option has arrived; the stock remains depressed relative to the realized and funded catalysts, with the India IPO as additional upside.